Researchers have successfully uncovered the molecular mechanisms by which bacterial cellulose patches stimulate the regeneration of plant wounds. - The regeneration process requires the activation ...
1d
Hosted on MSNHere’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage UniverseValuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's ...
The global artificial intelligence (AI) in biotechnology market size is calculated at USD 2,835 million in 2024 and is ...
The Central California Blood Center has a new CEO to spearhead the nonprofit's mission of providing blood to area hospitals.
Singapore continues to draw foreign investments despite geopolitical tensions and economic uncertainty. says EDB.
The rise in loan rate was confirmed by Saurabh Gadgil, chairman & managing director at PNG Jewellers, a listed firm. "Lease rates could rise from 1.5-2% to 3-4% and even 5% depending on the lender ...
Biotechnology is a broad discipline in which biological processes, organisms, cells or cellular components are exploited to develop new technologies. New tools and products developed by ...
They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...
A requisite majority of H-class shareholders did not approve the buyout, the companies said. "The proposed privatisation of the Company (Henlius) will not proceed and the listing of the H Shares ...
Primarily, Ascentage hopes to leverage the IPO proceeds to advance its pipeline. Around $50 million to $60 million, for instance, will help the biotech pursue approval for its BCL-2 blocker ...
The biotech firm's mRNA-1018 candidate posted positive results in a Phase 1/2 study launched in 2023. Moderna plans to move mRNA-1018 to a Phase 3 trial. Shares of Moderna (MRNA) took off Tuesday ...
In 2019, Stanford University professor Irv Weissman and a colleague published a paper that represented a new way to target some aggressive cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results